Get Results Faster, When It Matters Most
A Clinical Lab Partner You Can Trust
Infectious Disease • Transplant • Immunology • Allergy
• Innovation • Accuracy • Expertise • Speed
When you work with us, you're accessing over 40 years of diagnostic innovation and specialized expertise in infectious disease, pre- and post-transplant, allergy and immunology testing for immunocompromised and critical patients — plus a menu of over 3000 assays.
We are passionate about providing timely, actionable diagnostic information — never losing sight of the connection between the testing we perform and the patients you serve.
OUR VISION
To be a trusted healthcare leader improving patients' lives through innovation solutions, laboratory services, and partnerships.
OUR MISSION
Improving lives, one test at a time
OUR VALUES
Lead Humbly. Innovate Passionately. Improve Relentlessly. Work Responsibly. Act Honestly. Collaborate Openly. Maximize Talent.
eBook
This interactive eBook presents a synopsis of our operations, services, and, most importantly, our commitment to you and your patients. Viracor delivers accurate results, exceptional turnaround times, and personalized guidance that empowers you to make informed healthcare decisions for your patients.
We are passionate about providing timely, actionable information — never losing sight of the connection between the testing we perform and the patients you serve.
Commitment to Quality
Improving Relentlessly
Eurofins Viracor is committed to providing the highest quality diagnostics and service in compliance with all federal, state, and local laws and regulations, as well as, organizational policies and ethical standards.
We are driven by innovation and helping to improve patient outcomes. Regulatory compliance is essential in successfully bringing diagnostic testing platforms and new therapeutic agents to the marketplace.
View the full list of Lab Compliance, Licenses & Certificates, HIPAA, Privacy and More:
Dual-Gene Targets
Molecular Assays Designed to Help Reduce False Negatives and Under-quantification
The highly mutable nature of pathogens often proves challenging in molecular assay design. Traditional qPCR assays are designed so that a single primer and probe set targets one location within the pathogen genome. However, these single-target assays often prove inadequate to detect and quantify viral targets. Sequence polymorphisms in the assay target region can cause impaired primer or probe binding, which may result in significant under-quantification or a false negative result. To eliminate this possibility, Eurofins Viracor’s qPCR assays often target two regions within the pathogen genome, utilizing unique primer and probe sets for each target site. The driving principle behind our multiple-target assay design is that when a polymorphism occurs in one assay target, the additional sets of primers and probes for the alternate target region will still detect and accurately quantify the pathogen, and thus reduces the likelihood of under-quantification or a false negative result.
pathogen surveillance and assay refinement
Accounting for New Strains or Mutations that Might Otherwise be Missed
By utilizing nucleic acid sequence databases, each qPCR assay is regularly assessed to verify that new pathogen strains or genetic polymorphisms that arise will not lead to a false negative result. If a new pathogen strain or genetic polymorphism is identified that would lead to a false-negative result, our current qPCR assay is refined and revalidated to ensure that accurate test results are always reported.
We design each of our assays to account for all strains, serotypes, and clinical isolates - not just the most common ones. This is especially beneficial for immunocompromised patients who may be more likely to be infected with multiple or unusual strains. For example, the Adenovirus qPCR assay detects all known viral serotypes with equal sensitivity.
Additionally, we've designed and validated each assay to ensure there is no cross reactivity with other commonly occurring pathogens. This is critically important when testing for genetically similar but clinically divergent pathogens, such as BK virus and JC virus.
